Structure Mechanism Insights and the Role of Nitric Oxide Donation Guide the Development of Oxadiazole-2-Oxides as Therapeutic Agents against Schistosomiasis
- 17 September 2009
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 52 (20), 6474-6483
- https://doi.org/10.1021/jm901021k
Abstract
Schistosomiasis is a chronic parasitic disease affecting hundreds of millions of individuals worldwide. Current treatment depends on a single agent, praziquantel, raising concerns of emergence of resistant parasites. Here, we continue our explorations of an oxadiazole-2-oxide class of compounds we recently identified as inhibitors of thioredoxin glutathione reductase (TGR), a selenocysteine-containing flavoenzyme required by the parasite to maintain proper cellular redox balance. Through systematic evaluation of the core molecular structure of this chemotype, we define the essential pharmacophore, establish a link between the nitric oxide donation and TGR inhibition, determine the selectivity for this chemotype versus related reductase enzymes, and present evidence that these agents can be modified to possess appropriate drug metabolism and pharmacokinetic properties. The mechanistic link between exogenous NO donation and parasite injury is expanded and better defined. The results of these studies verify the utility of oxadiazole-2-oxides as novel inhibitors of TGR and as efficacious antischistosomal agents.Keywords
This publication has 62 references indexed in Scilit:
- Low Exchangeability of Selenocysteine, the 21st Amino Acid, in Vertebrate ProteinsMolecular Biology and Evolution, 2009
- PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO ReleaseScience, 2008
- A 1,536-Well-Based Kinetic HTS Assay for Inhibitors ofSchistosoma mansoniThioredoxin Glutathione ReductaseASSAY and Drug Development Technologies, 2008
- Helminth infections: the great neglected tropical diseasesJCI Insight, 2008
- A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomesProceedings of the National Academy of Sciences, 2008
- Identification of oxadiazoles as new drug leads for the control of schistosomiasisNature Medicine, 2008
- The pharmacology of nitroxyl (HNO) and its therapeutic potential: Not just the janus face of NOPharmacology & Therapeutics, 2007
- Quantitative high-throughput screening: A titration-based approach that efficiently identifies biological activities in large chemical librariesProceedings of the National Academy of Sciences, 2006
- Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at riskThe Lancet Infectious Diseases, 2006
- Mechanism of action of novel NO‐releasing furoxan derivatives of aspirin in human plateletsBritish Journal of Pharmacology, 2006